Osmo logoOS

About

Osmo is a technology company founded in 2022 with the mission of giving computers a sense of smell. Its core offering is an Olfactory Intelligence platform that combines molecular mapping, machine learning, and human artistry to digitally read, map, and reproduce scents. The company's research foundation includes five years of work conducted at Google Research.

The company's technical work spans olfactory neuroscience, machine learning, molecular mapping, and analytical chemistry. Its team brings together expertise from these fields alongside perfumery. A key demonstration of its capabilities was the first successful digital capture and re-synthesis of a naturally occurring smell, specifically that of a plum.

Osmo's product suite includes the Olfactory Intelligence platform and the Forge platform, an AI-driven tool designed for the flavor and fragrance industry to discover new fragrance ingredients. Forge is reported to discover new ingredients four times faster than traditional methods. The company secured $60 million in Series A funding.

Similar companies

Lytra logoLY

Lytra

Lytra is a Munich-based AI startup that has developed an industry-specific AI operating system for manufacturing service operations.

1 job
fgf brands logoFB

fgf brands

fgf brands uses robotics, AI, and supply chain technology to produce artisanal-style baked goods at industrial scale, aiming to eliminate synthetic ingredients.

1 job
Atoms logoAT

Atoms

Atoms builds physical automation systems combining robotics, software, and infrastructure for industries including food, mining, and transport.

1 job
Maven AGI logoMA

Maven AGI

Maven AGI is an enterprise AI platform that builds conversational AI agents for customer service, aiming to deliver accurate, autonomous support and personalized experiences.

1 job
Mistral logoMI

Mistral

Mistral develops and releases open-weight generative AI models to provide an alternative to proprietary AI systems.

Immunai logoIM

Immunai

Immunai is a biotech company that uses AI and single-cell multiomics to decode the human immune system and support pharmaceutical partners in accelerating drug discovery.